Allen Loyd V
International Journal of Pharmaceutical Compounding.
Int J Pharm Compd. 2019 Mar-Apr;23(2):123-130.
Process analytical technology was introduced by the U. S. Food and Drug Administration about 20 years ago to assist the pharmaceutical industry in making changes that should reduce batch failures, ensure performance, and enhance quality. Its premise is that "quality cannot be tested into preparations; it must be built-in or should be by design." One proposed advantage was to reduce end-product testing by ensuring each process was functioning properly. In compounding, there are a number of processes that could be advantageously incorporated into process analytical technology since end-product testing is not generally done due to the nature of compounding. The purpose of this article is simply to introduce the concept of process analytical technology into compounding with the understanding that it will take a number of years for it to be evaluated and implemented, even on a small scale. It is not feasible to do it all at once; just one step at a time. Since patient safety is uppermost in compounding, this concept should be considered.
大约20年前,美国食品药品监督管理局引入了过程分析技术,以协助制药行业进行变革,这些变革应能减少批次失败、确保性能并提高质量。其前提是“质量无法通过检测融入制剂中;它必须是内置的,或者应该是通过设计实现的”。一个预期的优势是通过确保每个过程正常运行来减少成品检测。在配制过程中,有许多过程可以有利地纳入过程分析技术,因为由于配制的性质,通常不进行成品检测。本文的目的仅仅是将过程分析技术的概念引入配制领域,同时要明白,即使是小规模地对其进行评估和实施也需要数年时间。一次性完成所有工作是不可行的;只能一步一个脚印。由于患者安全在配制过程中至关重要,因此应该考虑这一概念。